139 related articles for article (PubMed ID: 38824414)
21. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
Addeo A; Weiss GJ; Gyawali B
JAMA Netw Open; 2019 May; 2(5):e193684. PubMed ID: 31074821
[TBL] [Abstract][Full Text] [Related]
22. A novel method for interpreting survival analysis data: description and test on three major clinical trials on cardiovascular prevention.
Mengozzi A; Tricò D; Natali A
Trials; 2020 Jun; 21(1):578. PubMed ID: 32586346
[TBL] [Abstract][Full Text] [Related]
23. A survey of endpoint characteristics in periodontal clinical trials published 1988-1992, and implications for future studies.
Hujoel PP; DeRouen TA
J Clin Periodontol; 1995 May; 22(5):397-407. PubMed ID: 7601922
[TBL] [Abstract][Full Text] [Related]
24. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
25. Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review.
Langrand-Escure J; Rivoirard R; Oriol M; Tinquaut F; Rancoule C; Chauvin F; Magné N; Bourmaud A
PLoS One; 2017; 12(12):e0185536. PubMed ID: 29216190
[TBL] [Abstract][Full Text] [Related]
26. KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials.
Fell G; Redd RA; Vanderbeek AM; Rahman R; Louv B; McDunn J; Arfè A; Alexander BM; Ventz S; Trippa L
Database (Oxford); 2021 Jun; 2021():. PubMed ID: 34169314
[TBL] [Abstract][Full Text] [Related]
27. The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials.
Hayes AR; Chan DLH; Chan BA; Pavlakis N
J Neuroendocrinol; 2021 Sep; 33(9):e13015. PubMed ID: 34397130
[TBL] [Abstract][Full Text] [Related]
28. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Busacca A; Matranga D; Attanasio M; Reig M; Craxì A; Cammà C
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396833
[TBL] [Abstract][Full Text] [Related]
29. Outcomes, Interventions and Funding in Randomised Research Published in High-Impact Journals.
Grey P; Grey A; Bolland MJ
Trials; 2018 Oct; 19(1):592. PubMed ID: 30373636
[TBL] [Abstract][Full Text] [Related]
30. A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.
Wilson MK; Friedlander ML; Joly F; Oza AM
Oncologist; 2018 Feb; 23(2):203-213. PubMed ID: 29118265
[TBL] [Abstract][Full Text] [Related]
31. Sample Size Calculation in Oncology Trials: Quality of Reporting and Implications for Clinical Cancer Research.
Bariani GM; de Celis Ferrari AC; Precivale M; Arai R; Saad ED; Riechelmann RP
Am J Clin Oncol; 2015 Dec; 38(6):570-4. PubMed ID: 24401665
[TBL] [Abstract][Full Text] [Related]
32. Synthetizing Published Evidence on Survival by Reconstruction of Patient-Level Data and Generation of a Multi-Trial Kaplan-Meier Curve.
Messori A
Cureus; 2021 Nov; 13(11):e19422. PubMed ID: 34786276
[TBL] [Abstract][Full Text] [Related]
33. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
34. Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.
Campigotto F; Weller E
J Clin Oncol; 2014 Sep; 32(27):3068-74. PubMed ID: 25113767
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and predictors of bias in the reporting of primary efficacy and toxicity endpoints in randomized clinical trials of radiation oncology.
Tan TH; Chen D; Soon YY; Tey JC
J Med Imaging Radiat Oncol; 2016 Dec; 60(6):764-771. PubMed ID: 27396237
[TBL] [Abstract][Full Text] [Related]
36. Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group.
Everest L; Blommaert S; Tu D; Pater JL; Hay A; Cheung MC; Chan KKW
Value Health; 2022 Jul; 25(7):1157-1164. PubMed ID: 35779942
[TBL] [Abstract][Full Text] [Related]
37. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
38. A non-linear optimisation method to extract summary statistics from Kaplan-Meier survival plots using the published P value.
Irvine AF; Waise S; Green EW; Stuart B
BMC Med Res Methodol; 2020 Oct; 20(1):269. PubMed ID: 33126853
[TBL] [Abstract][Full Text] [Related]
39. A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses.
Xie W; Halabi S; Tierney JF; Sydes MR; Collette L; Dignam JJ; Buyse M; Sweeney CJ; Regan MM
JNCI Cancer Spectr; 2019 Mar; 3(1):pkz002. PubMed ID: 31360890
[TBL] [Abstract][Full Text] [Related]
40. Interpretation of clinical endpoints in trials of acute myeloid leukemia.
Medeiros BC
Leuk Res; 2018 May; 68():32-39. PubMed ID: 29524739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
